BioSpace News Archive

RELIEF THERAPEUTICS Holding AG announced that it has closed a definitive agreement to acquire all outstanding shares of AdVita Lifescience GmbH, a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.

Vacuum concentration is the method used for gentle drying, evaporation, purification, and preservation of thermally sensitive materials.

Hepatocellular carcinoma is the most common primary liver malignancy, accounting for 75% to 80% of liver cancers worldwide.

Products and services offered by players in the global dental insurance market i.e. the dental insurance services is a health insurance specifically designed for the purpose of dental care.

Radiosynthesis modules are offered as automated equipment for dispersed settings for the formulation as well as production of radiotracers.

XPhyto Therapeutics Corp. announces that its acquisition target, 3a-diagnostics GmbH has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection.

Eccogene, Inc. announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive amine oxidase /vascular adhesion protein-1, as a potentially novel therapy for patients with non-alcoholic steatohepatitis and osteoarthritis associated pain.

DiosCURE Therapeutics SE announced that it has signed an exclusive licensing agreement with the research and invention parties University of Bonn, University Hospital Bonn, Scripps Research and Macrostruct Holding & Consulting AB, for a broad suite of intellectual property, including the single-domain antibodies, DIOS-202, DIOS-203 and DIOS-301, currently in preclinical development as a potential differentiated, highly-efficacious therapy against SARS-CoV-2.

Itamar Medical Ltd., a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021.